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We have further tested the hypothesis that receptor-mediated modulation of KCNQ channels involves depletion
of phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
) by phosphoinositide-speciﬁc phospholipase C (PLC). We used
four parallel assays to characterize the agonist-induced PLC response of cells (tsA or CHO cells) expressing
M
 
1
 
 muscarinic receptors: translocation of two ﬂuorescent probes for membrane lipids, release of calcium from
intracellular stores, and chemical measurement of acidic lipids. Occupation of M
 
1
 
 receptors activates PLC and
consumes cellular PIP
 
2
 
 in less than a minute and also partially depletes mono- and unphosphorylated phospho-
inositides. KCNQ current is simultaneously suppressed. Two inhibitors of PLC, U73122 and edelfosine (ET-18-OCH
 
3
 
),
can block the muscarinic actions completely, including suppression of KCNQ current. However, U73122 also had
many side effects that were attributable to alkylation of various proteins. These were mimicked or occluded by
prior reaction with the alkylating agent N-ethylmaleimide and included block of pertussis toxin–sensitive G
proteins and effects that resembled a weak activation of PLC or an inhibition of lipid kinases. By our functional
criteria, the putative PLC activator 
 
m
 
-3M3FBS did stimulate PLC, but with a delay and an irregular time course. It
also suppressed KCNQ current. The M
 
1
 
 receptor–mediated activation of PLC and suppression of KCNQ current
were stopped by lowering intracellular calcium well below resting levels and were slowed by not allowing intra-
cellular calcium to rise in response to PLC activation. Thus calcium release induced by PLC activation feeds back
immediately on PLC, accelerating it during muscarinic stimulation in strong positive feedback. These experiments
clarify important properties of receptor-coupled PLC responses and their inhibition in the context of the living
cell. In each test, the suppression of KCNQ current closely paralleled the expected fall of PIP
 
2
 
. The results are
described by a kinetic model.
 
INTRODUCTION
 
Recent work attributes the long-known muscarinic
suppression of M-current K
 
 
 
 channels (Brown and
Adams, 1980) to a receptor-driven depletion of the
trace membrane lipid phosphatidylinositol 4,5-bisphos-
phate (PIP
 
2
 
) (Suh and Hille, 2002; Zhang et al., 2003;
Ford et al., 2004; Winks et al., 2005). In this hypothesis,
M-current channels require PIP
 
2
 
 to function, and acti-
vation of M
 
1
 
 muscarinic receptors results in destruction
of PIP
 
2
 
 via PIP
 
2
 
-speciﬁc PLC. Our work seeks to
strengthen the evidence for channel regulation by PIP
 
2
 
through a deeper understanding of the parameters of
PLC activation and pharmacology in living cells and by
asking if M-current modulation parallels PLC activation
and PIP
 
2
 
 hydrolysis under several conditions. Many
cytoplasmic enzymes and cytoskeletal proteins become
localized to membranes that contain PIP
 
2
 
 (Lemmon,
2003), and activities of many kinds of membrane pro-
teins, including ion channels and transporters, depend
on PIP
 
2
 
 levels in the plasma membrane (Hilgemann et
al., 2001; Suh and Hille, 2005), so now there is renewed
interest in understanding how PLC regulates phos-
phoinositide levels.
A large biochemical literature describes the signaling
properties of phosphatidylinositol (PI)-speciﬁc PLCs
in vitro (for review see Rhee, 2001). A few selected
points given here are relevant for our work. This
family of enzymes catalyzes the hydrolysis of PIP
 
2
 
 to
inositol 1,4,5-trisphosphate (IP
 
3
 
) and diacylglycerol
(DAG). The 
 
 
 
 isoform, PLC
 
 
 
, is activated by G protein–
coupled receptors that couple through G proteins of
the G
 
q
 
 family by direct action of G
 
 
 
q
 
GTP (Smrcka et
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al., 1991), and PLC
 
 
 
 can also be activated by G protein
 
  
 
 subunits (Rhee, 2001). Stimulation of G
 
q
 
-coupled
receptors in intact cells usually results in intracellular
Ca
 
2
 
 
 
 release mediated by gating of IP
 
3
 
 receptors,
which may be followed by additional Ca
 
2
 
 
 
 inﬂux from
the extracellular space. In test tube studies, the stimu-
lation of PLC depends on the local calcium concentra-
tion [Ca
 
2
 
 
 
] according to a broad, bell-shaped curve
with a maximum between 10 and 100 
 
 
 
M Ca
 
2
 
 
 
 (Ryu et
al., 1987b). In spite of considerable efforts, the phar-
macology of PLCs remains poorly developed and con-
troversial. Many papers show that several isoforms of
PLC are inhibited by the aminosteroid compound
U73122 and not by its “inactive” analogue U73343
(Smith et al., 1990). It is also inhibited by the ether
lipid analogue edelfosine (ET-18-OCH
 
3
 
) (Powis et al.,
1992). Finally, a recent report says that several isoforms
of PLC are activated by the benzenesulfonamide
 
m
 
-3M3FBS and not by its inactive analogue 
 
o
 
-3M3FBS
(Bae et al., 2003), but the speciﬁcity of this action has
been disputed (Krjukova et al., 2004).
Here we are interested in the in vivo properties of
PLC as they affect phosphoinositide metabolism and
KCNQ current. We use three nondestructive, continu-
ous monitors to follow the activity of PLC during stim-
ulation by transfected M
 
1
 
 muscarinic receptors or by
 
m
 
-3M3FBS in intact tsA-201 cells, and we use a bio-
chemical assay of phospholipids in Chinese hamster
ovary (CHO) cells. The M
 
1
 
 receptor pathway uses G
 
q/11
 
in tsA-201 cells (Hirdes et al., 2004; Suh et al.,
2004) and hence should selectively stimulate PLC
 
 
 
isoforms. Activation of PLC is monitored with a con-
focal ﬂuorescence microscope by observing two opti-
cal probes that track depletion of PIP
 
2
 
 and produc-
tion of IP
 
3
 
 and DAG. These widely used translocation
probes migrate between the cell membrane and cyto-
plasm during PLC activity. They are fusions of en-
hanced green ﬂuorescent protein (EGFP) with the
PIP
 
2
 
- and IP
 
3
 
-binding pleckstrin homology (PH) do-
main of PLC
 
 
 
1 or with the DAG-binding PKC cys-
teine-rich homology-1 domain, C1A (PKC-C1; Oancea
et al., 1998; Stauffer et al., 1998; Várnai and Balla,
1998). In addition, downstream effects of PLC are
monitored optically with a Ca
 
2
 
 
 
-sensitive ﬂuorescent
dye that reports the IP
 
3
 
-dependent release of Ca
 
2
 
 
 
from intracellular stores and Ca
 
2
 
 
 
 entry from the me-
dium. Further, we assay the relative sizes of various
phospholipid pools by biochemical methods. Finally,
parallel measurements are made of M current as ex-
pressed from KCNQ2 and KCNQ3 channel subunits
(KCNQ2/3 current).
Our paper asks the following questions. Is PIP
 
2
 
 de-
pleted by activation of M
 
1
 
 receptors, and to what extent
do the different reporters of PIP
 
2
 
 monitor the same sig-
nal? What are the consequences and mechanism of in-
hibition by U73122? What are the parameters of activa-
tion by 
 
m
 
-3M3FBS? Can PLC be activated at cellular
resting levels of cytoplasmic [Ca
 
2
 
 
 
]
 
i
 
? Is it speeded sig-
niﬁcantly by [Ca
 
2
 
 
 
]
 
i
 
 elevations, and is it slowed by
[Ca
 
2
 
 
 
]
 
i
 
 reductions? Does this regulation affect whether
PIP
 
2
 
 can be depleted signiﬁcantly in the plasma
membrane during receptor activation? Do changes of
KCNQ2/3 current mirror changes of PIP
 
2
 
?
 
MATERIALS AND METHODS
 
Cell Culture and Transfection
 
Human embryonic kidney tsA-201 (tsA) cells were cultured and
transiently transfected using Lipofectamine 2000 (Invitrogen)
with various cDNAs (Suh et al., 2004): M
 
1
 
-muscarinic receptor (1
 
 
 
g, from Neil Nathanson, University of Washington, Seattle,
WA), PH-PLC
 
 
 
1-EGFP (PH-EGFP, 0.25 
 
 
 
g, from P. De Camilli,
HHMI, Yale University, New Haven, CT), PKC-C1A-EGFP (C1-
EGFP, 0.25 
 
 
 
g, from T. Meyer, Stanford University, Stanford,
CA), PH-PLC
 
 
 
1-mRFP (PH-mRFP, 0.25 
 
 
 
g, from C. Kearn, Uni-
versity of Washington, using mRFP from Roger Tsien, University
of California, San Diego, CA), inositol 1,4,5-trisphosphate-5-phos-
phatase (IP
 
3
 
-5-P, 2 
 
 
 
g, from M. Iino, University of Tokyo, Japan),
the channel subunits KCNQ2 and KCNQ3 (Kv7.2 and Kv7.3, 1 
 
 
 
g,
from David McKinnon, State University of New York, Stony Brook,
NY), RGS-2 (2 
 
 
 
g, Guthrie Research Institute, Sayre, PA), and GFP
(0.1 
 
 
 
g) as a marker for transfection. TsA cells were maintained in
DMEM (Invitrogen) supplemented with 10% FCS and 0.2% peni-
cillin/streptomycin. In a few electrophysiological experiments we
used the mouse AtT-20 neuroendocrine cell line, which expresses
endogenous M
 
4
 
 muscarinic receptors and G protein–coupled in-
ward rectiﬁers (GIRK channels). They were grown in DMEM sup-
plemented with 10% horse serum and 0.2% penicillin/streptomy-
cin. For biochemical experiments we used a line of CHO cells sta-
bly transfected with M
 
1
 
-muscarinic receptors (CHO-M1 from N.J.
Buckley and D.A. Brown, University College, London, UK). They
were grown in F-12K nutritional mixture with 10% bovine calf se-
rum and 1% penicillin/streptomycin.
 
Reagents
 
The muscarinic receptor agonist oxotremorine-M (oxo-M) was
used at 10 
 
 
 
M. Chemicals were purchased from Sigma-Aldrich,
except U73122 (1-[6-[[17 
 
 
 
-3-methoxyestra-1,3,5(10)-trien-17-
yl]amino]hexyl]-1H-pyrrole-2,5-dione) and U73343 (Research
Biochemicals), BAPTA-AM and BAPTA (Molecular Probes),
 
m
 
-3M3FBS (2,4,6-trimethyl-N-(meta-3-triﬂuoromethyl-phenyl)-
benzene-sulfonamide) and 
 
o
 
-3M3FBS (Tocris), and edelfosine
(Calbiochem).
 
Confocal Imaging and Analysis
 
TsA cells were imaged 24–48 h after transfection on poly-
 
l
 
-lysine–
coated coverslips (Suh et al., 2004). The external Ringer’s solu-
tion used for confocal observations and for current recording
contained (in mM): 160 NaCl, 2.5 KCl, 2 CaCl
 
2
 
, 1 MgCl
 
2
 
, 10
HEPES, and 8 glucose, adjusted to pH 7.4 with NaOH. Images
were taken every 5 s on a Leica TCS/MP confocal microscope at
room temperature and processed with Metamorph (UIC) and
Igor Pro 4.0 (Wavemetrics, Inc.). To obtain averaged time
courses, the ﬂuorescence intensity 
 
F
 
 over a given region of the cy-
toplasm or nucleus was usually normalized to the average inten-
sity for the 30 s before agonist application 
 
F
 
0
 
 (
 
F
 
/
 
F
 
0
 
). Images are
shown here in negative contrast so that the brightest ﬂuores-
cence appears black. 
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Electrophysiology and Calcium Photometry
 
TsA cells were whole-cell clamped at room temperature 24–48 h
after transfection (Suh et al., 2004). The pipette solution con-
tained (in mM): 175 KCl, 5 MgCl
 
2
 
, 5 HEPES, 0.1 BAPTA, 3
Na
 
2
 
ATP, 0.1 Na
 
3
 
GTP, pH 7.4 adjusted with KOH. For the experi-
ments of Fig. 8 (E and F), the pipette solution was sometimes
supplemented with 10 mM calcium, 1 
 
 
 
M thapsigargin, 100 
 
 
 
g/
ml pentosan polysulfate (an IP
 
3
 
 receptor blocker; Bezprozvanny
et al., 1993), and more BAPTA as described. The special pipette
solution with 10 mM CaCl
 
2
 
 and 20 mM BAPTA has an estimated
free [Ca
 
2
 
 
 
] of 128 nM. When measuring the rates of induction
and recovery from muscarinic inhibition of the current, we ap-
plied test and control solutions rapidly to the 100 
 
 
 
l chamber
(ﬂow rate of 1.5 ml min
 
 
 
1
 
) in the vicinity of the recorded cell.
The solutions exchanged in 
 
 
 
6 s. Recordings were performed
using a HEKA EPC-9 ampliﬁer with Pulse software (HEKA Elek-
tronik). Data analysis was done using Igor Pro 4.0. Cells were
held at a holding potential of 
 
 
 
20 mV, and 500-ms test pulses to
 
 
 
60 mV were given every 4 s. Reported values (I
 
 
 
20 mV
 
) are mean
outward current taken at 
 
 
 
20 mV just before each step to 
 
 
 
60
mV. Recordings started 
 
 
 
5 min after breakthrough. Some exper-
iments studied inward rectiﬁer currents in AtT-20 cells, which
were recorded using the same pipette solution but with a bath so-
lution where the Na
 
 
 
 and K
 
 
 
 concentrations were changed to
125 Na
 
 
 
 and 40 K
 
 
 
. For photometry, cells were preloaded with
indo-1-AM (Molecular Probes) and not subjected to patch
clamp. The ratio of background-corrected 405/505 nm emission
elicited by excitation at 365 nm was used to calculate absolute
[Ca
 
2 ]i levels (Shapiro et al., 2000).
Analysis of Acidic Membrane Lipids
Membrane lipids of CHO-M1 cells were analyzed as previously de-
scribed (Nasuhoglu et al., 2002a). In brief, acidic phospholipids
were extracted and deacylated to give the parent glycero-head-
groups, which were then separated by HPLC and detected by sup-
pressed conductivity. The relative quantity of each headgroup is
expressed as the percentage of all acidic lipid headgroups.
Student’s unpaired t test (2 tailed), or, when indicated, a one-
way ANOVA with a Bonferroni post-hoc test for multiple compar-
isons, was used to test for signiﬁcance. Where error bars are
shown, they represent SEM
Online Supplemental Material
The supplemental material for this paper comprises one ﬁgure
and the listing of a computer program (available at http://
www.jgp.org/cgi/content/full/jgp.200509309/DC1). Fig. S1
shows changes in the voltage dependence of activation of KCNQ
current caused by addition of U73122 or N-ethylmaleimide. The
computer program describes the elementary model for translo-
cation of PH-EGFP and C1-EGFP probes between cytoplasm and
nucleus.
RESULTS
Two Translocation Probes Report Activation of PLC 
via M1 Receptors
We start with control experiments to understand the
properties of our two translocation probes. Fig. 1 A
shows the M1 receptor–mediated activation of PLC as
seen with the PH-EGFP probe (top) and the C1-EGFP
probe (bottom) in separate cells before, during, and af-
ter a 3-min application of the muscarinic agonist oxo-M
(10  M). The closed green lines outline a cytoplasmic
region of interest and the red lines, a nuclear region of
interest. Since the PH-EGFP has afﬁnity for PIP2 and
IP3, it binds to the PIP2 in the plasma membrane at rest
(dark cell outline in ﬁrst frame), translocates to the cy-
toplasm as oxo-M stimulation of PLC causes IP3 to rise
in the cytoplasm and PIP2 to fall at the membrane
(darkened cytoplasm in second frame), and returns to
the plasma membrane after oxo-M is washed off while
IP3 is being hydrolyzed and PIP2 resynthesized (last
frame). The rise and fall of cytoplasmic PH-EGFP ﬂuo-
rescence is reversible and repeatable (Fig. 1 B, green).
Similar experiments with the C1-EGFP probe, which
binds to DAG, show a reciprocal time course of translo-
cation. That probe is uniformly distributed in the cyto-
plasm and nucleus at rest (dark cytoplasm in Fig. 1 A
and symbols in Fig. 1 C), reporting little DAG on any
membrane, but migrates to the plasma membrane as
oxo-M stimulation of PLC produces DAG there, and re-
turns to the cytoplasm when oxo-M removal allows DAG
to decline. Oxo-M affects the two probes with approxi-
mately equal potency, giving midpoints for peak translo-
cation near 0.25 and 0.28  M oxo-M (Fig. 1, D and E).
The initial migration takes 10–15 s (Fig. 1, B and C;
points are 5 s apart), and the recovery takes 100–200 s.
The cytoplasmic concentration change of both
probes sags during the 3-min-long application of oxo-M
(Fig. 1, B and C) as if there were some kind of desensiti-
zation and reversal of the PLC response. This implied
that there might be some unexpected features to PIP2
metabolism. However, further analysis suggests that the
sag is at least partly caused by an additional slow ex-
change of probe molecules between the nucleus and cy-
toplasm. Compare the thin red traces of nuclear ﬂuo-
rescence in Fig. 1 (B and C) with the heavier green
traces of cytoplasmic ﬂuorescence. At rest, the nuclear
and cytoplasmic concentrations are similar. During re-
peated stimulation and wash, the nuclear ﬂuorescence
starts to rise after the cytoplasmic ﬂuorescence rises,
and to fall after the cytoplasmic ﬂuorescence falls. The
same can be seen in the pictures of Fig. 1 A, where the
nuclear and cytoplasmic ﬂuorescence are about equal
at rest (Fig. 1 A, top left), and early in the oxo-M treat-
ment the nucleus (clear disk inside cell) remains much
lighter than the cytoplasm, but after washout of oxo-M,
the nucleus remains a little darker than before (Fig. 1 A,
top right). Simple modeling (see APPENDIX and Fig.
11) shows that the nuclear ﬂuorescence tracks the cyto-
plasmic ﬂuorescence with an exponential relaxation
time constant   of  360 or 225 s (for PH-EGFP and C1-
EGFP, respectively), equivalent to nuclear envelope per-
meability coefﬁcients of 0.0025 or 0.004  m s 1. Slow
exchange with the nucleus accounts for perhaps half of
the sag of the response during oxo-M, for most of the
observed overshoot in the recovery of C1-EGFP after
oxo-M is removed, and for the signiﬁcant background246 Regulation of PLC, PIP2, and M Current
level of cytoplasmic and nuclear PH-EGFP before oxo-M
and of C1-EGFP during oxo-M. Thus the background
level can be described as an equilibrium distribution of
probe rather than as a nonspeciﬁc binding.
The nearly reciprocal movement of the two probes is
highlighted in Fig. 1 F, which is from a simultaneous
two-color ﬂuorescence measurement in one cell. For
this experiment, the PH domain is fused to a mono-
meric red ﬂuorescent protein (mRFP), and the C1 do-
main probe is fused to green EGFP. As the red ﬂuores-
cent protein was more subject to photobleaching with
our illumination settings, it shows a superimposed
gradual decline over the 400-s period. In a series of two-
color experiments with these probes, the exponential
time constants for initial translocation and the half
times for ﬂuorescence recovery for oxo-M are  trans  
16   2 s and t1/2 rec   36   6 s for PH-mRFP (n   5)
and  trans   19   1 s and t1/2 rec   87   7 s for C1-EGFP
(n   5) (Fig. 1 G). The initial translocation time is sim-
ilar, but recovery of the C1-EGFP probe is signiﬁcantly
slower than that of the PH-mRFP probe. However,
there is no a priori expectation that the recoveries
would be similar since the metabolic pathways that de-
phosphorylate IP3, synthesize more PIP2, and phosphor-
ylate DAG are different and independent.
The Inhibitor U73122 Has Complex Actions
U73122 is a PLC inhibitor that is widely used as a quick
test for the involvement of PLC in a signaling pathway.
In our experiments, U73122 strongly uncoupled activa-
tion of PLC by receptors as expected. Fig. 2 (A and B)
shows confocal experiments with U73122 and its rela-
tively inactive analogue U73343 using the DAG probe
(C1-EGFP). Again, oxo-M is applied twice for 3 min.
The DAG probe translocates to the membrane during
the ﬁrst oxo-M application, but not after a 5-min appli-
cation of U73122 (2.5  M; Fig. 2 A; n   10). The con-
trol compound U73343 seems inactive as it does not
prevent the translocation (Fig. 2 B; n   3). These ro-
bust effects seem readily interpreted as a simple inhibi-
tion of M1 receptor–stimulated PLC activation and
DAG production. In these experiments, U73122 by it-
self tends to augment the cytoplasmic ﬂuorescence of
the DAG probe in resting cells as if it has released some
of the probe from the membrane (Fig. 2 A).
Similar experiments with the IP3/PIP2 probe (PH-
EGFP) suggest a more complicated picture (Fig. 2, C
and D). Again, U73122 fully blocks the translocation in-
duced by oxo-M; however, even without oxo-M, U73122
Figure 1. Oxo-M translocates two complementary optical probes
of PI metabolism. (A) Confocal images of the PH-EGFP or C1-
EGFP probes transiently expressed in separate tsA cells, shown in
negative contrast (ﬂuorescence is dark). Cells (both presumably
recently divided) before oxo-M, after 50 s of 10  M oxo-M, and
after 200 s of washout. The optical sections pass through the
nucleus, which is centered in the frame and has a red circular
region of interest. The cytoplasm has a green region of interest.
(B) Time course (5-s sample intervals) of mean ﬂuorescence per
pixel in a cytoplasmic (green line and symbols) and a nuclear
region-of-interest (red line) of a cell during two 3-min applications
of oxo-M with the PH-EGFP probe (different cell from A). (C)
Cytoplasmic and nuclear ﬂuorescence in a similar experiment, but
with the C1-EGFP probe. (D) Dose–response relation for translo-
cation of the PH-EGFP probe. Cytoplasmic ﬂuorescence (F)
relative to ﬂuorescence at the beginning of the experiment (F0)
for n   4–6 cells per point. (E) Dose–response experiments with
the C1-EGFP probe, n   4–8 cells per point. Here F0 is the last
measured control point before each oxo-M application. (F) Repre-
sentative time courses of cytoplasmic translocation (5-s sample
intervals) for C1-EGFP (green) and PH-mRFP (red) measured
simultaneously at two wavelengths in the same cell. (G) Exponen-
tial time constant for translocation ( ) during oxo-M application
and half-time for recovery after washout (n   5). *, P   0.016
indicates signiﬁcant difference from the recovery rate of PH-mRFP.Horowitz et al. 247
initiates a slow translocation of the probe (Fig. 2 C; n  
15 cells). This translocation is 30 times slower than that
with oxo-M. As expected, the control compound U73343
does not block oxo-M action (Fig. 2 D; n   7), although
in some experiments at high concentration, U73343 by
itself seemed to induce a slight translocation. Transloca-
tion occurs with U73122 alone even when the extracellu-
lar solution includes no calcium (unpublished data; n  
7). These observations suggest the working hypothesis
that U73122 efﬁciently blocks activation by the Gq path-
way, as is widely reported, but it is also a very weak ago-
nist of PLC. Fig. 3 A examines the time course of these
effects. U73122 (3  M) was applied for 0, 0.5, 1, 2, 3, or
5 min. According to the PIP2/IP3 probe, receptor-induced
activation of PLC is half blocked after just 0.5 min of
3  M U73122, whereas the U73122-induced transloca-
tion of probe (closed symbol) takes signiﬁcantly longer,
and is half induced after 3 min of U73122.
Calcium photometry measurements are consistent
with our working hypothesis (Fig. 2, E and F). A ﬁrst
application of oxo-M raises [Ca2 ]i strongly. The initial
Figure 2. U73122 blocks the muscarinic translocation of two
optical probes, intracellular calcium responses, and modulation of
KCNQ current. All traces are representative experiments from
single cells. (A and B) Time courses of cytoplasmic ﬂuorescence in
representative confocal translocation experiments with the C1-
EGFP probe before and during perfusion of oxo-M (10  M, 3
min), ﬁrst without and then with 5-min treatments with 2.5  M
U73122 (A) or U73343 (B). Insets show the structure of these
compounds. (C and D) Similar confocal experiments in cells
expressing the PH-EGFP probe and using 3  M U73122 or
U73343. (E and F) Indo-1 photometry Ca2  measurements showing
block by U73122 but not U73343 of oxo-M (60 s) induced [Ca2 ]i
elevations. (G and H) Electrophysiological experiments (4-s
sample intervals) showing action of 3  M U73122, 2 min applica-
tion (G) or 5 min application (H), on KCNQ2/3 current and its
modulation by oxo-M.
Figure 3. Time course of actions of U73122. (A) Cells are preex-
posed to U73122 for 0, 0.5, 1, 2, 3, or 5 min and to 5, 4.5, 4, 3, 2, or
0 min of control solution before a 3-min application of oxo-M.
Bars show this protocol of treatments. Increment in cytoplasmic
PH-EGFP ﬂuorescence measured at 5 min (at the end of the
preexposure period and before the oxo-M; ﬁlled circles) and the
additional increment of ﬂuorescence after oxo-M application
(open circles). (B) Cells are preexposed to U73122 for 0, 1, 2, 3,
or 5 min and to 5, 4, 3, 2, or 0 min of control solution before a
30-s application of oxo-M. Depression of KCNQ current measured
at 5 min and the additional suppression of current after oxo-M
application.248 Regulation of PLC, PIP2, and M Current
calcium rise comes from intracellular stores, presum-
ably by IP3-dependent release, but the later plateau re-
quires extracellular calcium (unpublished data; n   5
cells) and probably involves calcium entry that depends
on store emptying. Induction of [Ca2 ]i elevations by
agonist is fully blocked after prior exposure to U73122
(Fig. 2 E; n   5) but not after the inactive analogue
U73343 (Fig. 2 F; n   4). Nevertheless, U73122 alone
raises [Ca2 ]i a little, albeit very slowly (Fig. 2 E; n   6).
Experiments with KCNQ2/3 current give a similar
picture (Fig. 2, G and H). Fig. 2 G shows the expected
suppression of current by oxo-M (measured at  20
mV) and its prevention by U73122. The initial control
application of oxo-M for 30 s strongly suppresses cur-
rent as PLC is activated and PIP2 is depleted (Suh and
Hille, 2002; Suh et al., 2004). The suppression is re-
versible. The time course of this current modulation is
reminiscent of the time course of PIP2 hydrolysis re-
ported by the PH-EGFP probe (Fig. 2 C), although the
recovery of current is consistently a little slower than
the recovery of PH-EGFP distribution. Next, when
U73122 is applied for 2 min, the current starts to in-
crease rapidly, an unexpected result, and then to de-
cline steadily below the initial level. Subsequent appli-
cation of oxo-M is ineffectual, indicating again that M1
receptor coupling to PLC has been powerfully blocked
(Fig. 2 G, n   5). With a 5-min application of U73122,
the initial augmentation is similar but the current de-
clines considerably during the exposure to the inhibi-
tor (Fig. 2 H, n    12). Fig. 3 B examines the time
course of these effects. U73122 (3  M) was applied for
1, 2, 3, 4, or 5 min. The block of receptor coupling
(open symbols) is almost complete after a 1-min expo-
sure to U73122, and the U73122-induced depression
of current (closed symbols) is still only partial after 3
min of U73122.
Why does the current increase and then decrease
during U73122? We begin with the transient augmenta-
tion, which Stemkowski et al. (2002) have also de-
scribed for endogenous M current in frog sympathetic
neurons. We asked if it could be due to a changed volt-
age dependence of activation by measuring the ampli-
tudes of tail currents at  70 mV after 500-ms depolar-
izations to different test potentials. Indeed, this proto-
col revealed that U73122 shifts the voltage dependence
of KCNQ2/3 channel activation to more negative po-
tentials by 14   3 mV (n   4; see Fig. S1 A, available at
http://www.jgp.org/cgi/content/full/jgp.200509309/
DC1). Such a shift would allow more channels to open
at  20 mV since steady-state activation at that voltage is
normally incomplete (only 52%) and would be in-
creased to 80% by the drug (Fig. S1 A). The subse-
quent decline of current is consistent with the hypothe-
sis that U73122 acts as a very weak agonist of PLC, re-
sulting in a slow decline in the membrane PIP2 and
hence of the current. Again, the rate of decline is  30
times slower than the rapid suppression by oxo-M, sug-
gesting that PLC is turned on to only 3–4% of the max-
imum level achieved with receptor activation.
The actions of U73122 were sufﬁciently complex that
we wanted to test another inhibitor of PLC. We tried
the lipid-like, anti-neoplastic agent edelfosine (ET-18-
OCH3). As is shown in Fig. 4 (A and B), this compound
(10  M for 30 min) entirely prevented the muscarinic
Figure 4. Edelfosine blocks PLC activation.
Cells were preincubated with vehicle or 10  M
edelfosine for 30 min at 37 C and then used in
the experiment. Data are representative of
three to ﬁve separate experiments for cells
stimulated with 10  M oxo-M. (A and B)
Translocation of the PH-EGFP probe in control
(A) or edelfosine-treated (B) cells. (C and D)
Modulation of KCNQ2/3 current in control
(C) or edelfosine-treated (D) cells.Horowitz et al. 249
translocation of the PH-EGFP probe and the muscar-
inic inhibition of KCNQ currents (at 15 min the action
of edelfosine was strong but incomplete). Further-
more, by itself it did not induce the rise and inhibition
of KCNQ current or the slow migration of the PH-
EGFP probe seen with U73122. These actions of edel-
fosine are consistent with simple inhibition of PLC, and
we interpret the additional effects of U73122 as side ef-
fects with other mechanisms.
Some Actions of U73122 May Represent Alkylation
The literature on U73122 contains numerous sugges-
tions of side effects that could not be attributed to sim-
ple block of PLC (see DISCUSSION). We decided to in-
vestigate the initial augmentation of KCNQ current
with U73122 as such a side effect. The only structural
difference between U73122 and U73343 is one double
bond (Fig. 2, A and B, insets) that makes U73122
chemically reactive. U73122 is an N-substituted maleim-
ide, which like N-ethylmaleimide (NEM) should be
able to alkylate cysteine  SH groups, tethering the en-
tire U73122 compound covalently to the cysteine.
U73343 is the corresponding unreactive succinimide.
Both the augmentation of KCNQ current and the nega-
tive shift of activation with U73122 reminded us of aug-
mentations and shifts induced by NEM acting on cys-
teine residues of KCNQ channels (Roche et al., 2002;
Li et al., 2004). We veriﬁed that the shifts are quite sim-
ilar (Fig. S1 B). Therefore we sought to test the hypoth-
esis that U73122 can act as a hydrophobic- or mem-
brane-targeted version of NEM, capable of reacting
with  SH groups generally.
Figure 5. NEM mimics or occludes several actions of U73122. NEM is applied at 100  M for 120 s and U73122 is applied at 3  M
throughout. All traces are for representative single cells. (A–D) KCNQ2/3 current in tsA cells and its modulation by oxo-M. (A) NEM
alone. Inset shows structure of NEM. (B) NEM followed by U73122. (C) U73122 followed by NEM. (D) Summary of A–C. Left axis is
percent inhibition of KCNQ current by oxo-M application. Right axis is fold increase of KCNQ current with NEM application. The cells
were untreated or pretreated with NEM or U73122. *, P   0.05, compared with control. (E–G) Inward rectiﬁer K current at  100 mV
(ﬁlled circles) and holding current at  40 mV (open circles) in AtT-20 cells. (E) Effect of NEM. (F) Effect of U73122. (G) Summary of K 
current increase. Number of cells is given in parentheses. (H and I) Cytoplasmic ﬂuorescence of translocation probes C1-EGFP (H) and
PH-EGFP (I) during NEM, U73122, and oxo-M.250 Regulation of PLC, PIP2, and M Current
Fig. 5 A shows powerful augmentation of KCNQ2/3
current by 120 s of 100  M NEM, as previously re-
ported (Roche et al., 2002). The augmentation is con-
sistently larger than that with U73122. Somewhat like
U73122, NEM also slows and decreases the subsequent
response to oxo-M; however, this effect is only partial.
Fig. 5 B shows that prior NEM treatment prevents
U73122 from augmenting KCNQ current and also
from subsequently decreasing it, but prior NEM does
not prevent U73122 from fully uncoupling receptor ac-
tivation from PLC. Similarly, prior U73122 treatment
prevents NEM for augmenting KCNQ current (Fig. 5
C). The effects summarized in Fig. 5 D suggest that
both the augmentation and the subsequent decline of
current with U73122 are side effects dependent on
alkylating accessible  SH groups. As expected for such
reactions, all actions of NEM and of U73122 were irre-
versible on the time scale of our experiments.
As a further test of the alkylation hypothesis, we asked
if U73122 mimics another effect of NEM on signaling to
ion channels. Previously we have shown that NEM
readily blocks electrophysiological responses due to per-
tussis toxin–sensitive G proteins (Gi/Go), presumably by
alkylating the same G protein cysteine residue that per-
tussis toxin ADP ribosylates (Shapiro et al., 1994). One
such response is the pertussis toxin–sensitive opening of
inward rectiﬁer GIRK channels by muscarinic agonists
acting on M2 receptors (Pfafﬁnger et al., 1985). Fig. 5 E
shows that oxo-M acting via endogenous M4 receptors
activates this inward current in AtT-20 cells, and that
NEM completely uncouples the muscarinic effect as was
expected from block of Gi/Go. Similarly, U73122 uncou-
ples the M4 muscarinic action (Fig. 5 F; see summary
Fig. 5 G) even though PLC is not involved. Again,
U73122 mimics an effect of NEM, this time on pertussis
toxin–sensitive G proteins. Treatment with U73122 also
reduces the holding current somewhat.
Our last example of occlusion of U73122 actions by
NEM returns to the translocation probes. Prior treat-
ment with NEM eliminates the small augmentation of
cytoplasmic ﬂuorescence by U73122 seen with C1-
EGFP (Fig. 5 H; n   4; compare with Fig. 2 A) and the
large slow augmentation seen with PH-EGFP (Fig. 5 I;
n   7; compare with Fig. 2 C). Thus by many criteria,
U73122 and NEM mimic and occlude each others’ ac-
tions. However, NEM did not occlude one action of
U73122; namely, it did not prevent U73122 from fully
uncoupling muscarinic activation of PLC as judged by
the translocation assays (n   11). In addition, by itself
NEM did not induce translocation of either probe,
even with a 5-min treatment (unpublished data).
Phosphoinositides Are Hydrolyzed
We undertook an analysis of acidic phospholipids of
CHO-M1 cells during treatments with carbachol,
U73122, and NEM. These cells express M1 receptors
stably. Using deacylated headgroups, our method mea-
sures the relative abundance of six acidic lipids: phos-
phatidylinositol (PI), phosphatidylinositol 4-phos-
phate (PIP), PIP2, phosphatidylserine, cardiolipin, and
phosphatidic acid (Nasuhoglu et al., 2002a). Fig. 6 re-
ports PI, PIP, and PIP2 as percent of the total of the six
acidic lipid classes measured. In unstimulated cells, PI
is almost 50% of the total and PIP and PIP2 are only
 1% each, truly trace phospholipids. A 1-min carba-
chol treatment strongly reduces PIP2 and PIP (to 7%
and 12% of control, respectively) and slightly but sig-
niﬁcantly reduces PI (to 95% of control), consistent
with a powerful muscarinic activation of PLC  deplet-
ing the major cellular pools of PIP2. A 5-min treatment
with 5  M U73122 alone also reduces PIP2 and PIP, al-
though not as much as carbachol, and it renders subse-
quent treatment with carbachol ineffectual. These re-
sults would be consistent with a weak activation of PLC
by U73122, and a total block of carbachol action. Alter-
native interpretations are considered in DISCUSSION.
Figure 6. Carbachol and U73122 decrease PIP2. Size of PI, PIP,
and PIP2 pools in CHO-M1 cells expressed relative to the sum of
six acidic phospholipids. Treatments were: none (Control), 1 min
of 200  M carbachol (CCh), 5 min of 5  M U73122 (U73122
Control), U73122 followed by 1 min of carbachol with U73122
(U73122 CCh), and 2 min of 100  M NEM. Number of cells is
given in parentheses.Horowitz et al. 251
NEM did not change the lipid composition in 2 min,
but in further measurements not shown, it did reduce
PIP2 and PIP by 35 and 50%, respectively, in 5 min. Also
we mention that both PIP and PIP2 levels consistently
rebounded  50% back toward control levels after 10
min in the continued presence of agonist.
Since the stable CHO-M1 cells used for chemical as-
says were different from the tsA cells used in the rest of
our experiments, we checked the oxo-M–induced mod-
ulation of KCNQ2/3 current and the translocation of
the PH-EGFP probe in them. The speed and amplitude
of the muscarinic current modulation and of the probe
migration were virtually identical to those in tsA cells,
where the M1 receptor had been introduced by tran-
sient transfection (n    5–8). We conclude that the
quantitative parameters of KCNQ2/3 current inhibi-
tion and PI metabolism are indistinguishable in the two
cell lines.
m-3M3FBS Activates PLC with a Delay
In search of other practical ways to activate PLC, we
then studied the putative PLC activator m-3M3FBS and
its control compound o-3M3FBS (Bae et al., 2003). We
found that the meta compound causes migration of the
PH-EGFP and C1-EGFP probes (Fig. 7, A and B), and it
induces suppression of the KCNQ2/3 current (Fig. 7
C). By these criteria, it activates PLC. Judging from the
relative steepness of the traces, the apparent activation
by m-3M3FBS is relatively strong once it starts but is still
a little weaker than for the maximal activation by oxo-M.
The action begins abruptly after a variable delay of
several hundred seconds and sometimes it reverses
spontaneously for 200 s, only to start up again. The
control compound o-3M3FBS induces no migration of
the probes and no suppression of current beyond the
usual rundown that would be seen in control condi-
tions (Fig. 7, D–F). In our previous work, we have
Figure 7. m-3M3FBS stimulates PLC. Panels show time courses for each of three to six individual cells of scaled cytoplasmic ﬂuorescence
of PH-EGFP (A, D, and G) Scaled cytoplasmic ﬂuorescence of C1-EGFP (B, E, and H) and relative KCNQ2/3 current (C, F, and I). To
scale the ﬂuorescence, each record was normalized to its own maximum and minimum. (A–C) Cells treated with oxo-M and then with 50
 M m-3M3FBS. (D–F) Cells treated with oxo-M and then with 50  M o-3M3FBS. (G–I) Cells were cotransfected with RGS2 protein (24 h)
and then treated with oxo-M followed by 50  M m-3M3FBS.252 Regulation of PLC, PIP2, and M Current
shown that coexpression of the Gq/11-speciﬁc regulator
of G protein signaling RGS-2 blocks oxo-M–induced
migration of PH-EGFP and suppression of KCNQ2/3
current in these cells (Suh et al., 2004). This is evi-
dence that the normal muscarinic action via M1 recep-
tors requires participation of the G protein Gq/11. Coex-
pression of RGS-2 does not block the activation of PLC
by m-3M3FBS (Fig. 7, G–I). Hence the activator must
work downstream of muscarinic receptors and Gq.
PLC Needs Calcium
We explored the [Ca2 ]i dependence of the muscarinic
activation of PLC by buffering cellular [Ca2 ]i to differ-
ent levels. The principal questions were whether PLC
in live cells can be activated when Ca2  is well below
normal, whether the IP3-induced release of Ca2  from
intracellular stores exerts positive feedback to acceler-
ate PLC, and whether modulation of KCNQ current
has the same calcium dependence.
The experiments in Fig. 8, A, C, and E, each include
three different intracellular conditions. In the top pan-
els, [Ca2 ]i is relatively unbuffered (control). In the
middle panels, [Ca2 ]i is strongly buffered under con-
ditions intended to mimic and stabilize resting levels.
In the lower panels, [Ca2 ]i is strongly buffered using
conditions intended to clamp it well below normal rest-
ing levels. In the photometry and confocal experiments
(Fig. 8, A–D), which used intact cells, the Ca2  buffer-
Figure 8. Buffering [Ca2 ]i depresses muscarinic activation of PLC. (A) Oxo-M-evoked [Ca2 ]i rises with different intracellular Ca2 
buffering: no exogenous buffer (top) or pretreatment with thapsigargin (20 min, 1  M) and loaded with BAPTA-AM (50  M for 20 min)
either in the presence of extracellular Ca2  (2 mM) (middle) or in the absence of extracellular Ca2  (plus 0.5 mM EGTA) (bottom). (B)
Means of experiments as in A. *, P   0.001, compared with control. (C) Oxo-M–induced cytoplasmic ﬂuorescence increases (PH-EGFP)
under the same three buffering conditions as in A. (D) Means of experiments as in C and two additional sets using no BAPTA/AM to
buffer [Ca2 ]i. *, P   0.001, compared with control. (E) Oxo-M–induced suppression of KCNQ2/3 current with different intracellular
Ca2  buffers in the whole-cell pipette: 0.1 BAPTA (top); 20 BAPTA   10 CaCl2   100  g/ml PPS (middle); or 20 BAPTA   0 CaCl2
(bottom). The middle and lower cells were also pretreated with 1  M thapsigargin. (F) Mean amplitude of inhibition and time constant
( ) for current suppression;   for calcium-free condition not determined. *, P   0.001, compared with % inhibition of control. **,
P   0.01, compared with   of control. ***, P   0.05, compared with % inhibition of control.Horowitz et al. 253
ing was achieved by preloading membrane-permeant
BAPTA-AM and by pretreating with thapsigargin to al-
low any intracellular stores to empty. The [Ca2 ]i level
was manipulated by doing these incubations and the
subsequent measurements either in 2 mM Ca2 –con-
taining or Ca2 -free solutions (with EGTA). As ex-
pected, the [Ca2 ]i measurements (Fig. 8, A and B)
showed that [Ca2 ]i rises briskly after the muscarinic
stimulus when it is unbuffered, and it does not rise sig-
niﬁcantly when it is strongly buffered at either normal
or subnormal levels. The confocal experiment (Fig. 8,
C and D) showed that, relative to controls, the oxo-M–
induced translocation of PH-EGFP still occurs but is
slowed and reduced in ﬁnal amplitude when [Ca2 ]i is
buffered at resting levels. Prior emptying of intracellu-
lar Ca2  stores with thapsigargin without buffering in-
ternal Ca2  with BAPTA/AM reduces subsequent oxo-
M–induced translocation of PH-EGFP to a similar ex-
tent (Fig. 8 D). Translocation is nearly absent when
[Ca2 ]i is held at reduced levels (Fig. 8 C, bottom). To-
gether, these experiments show that muscarinic acti-
vation of PLC requires some free Ca2 . PLC can be
activated at resting [Ca2 ]i levels, but activation is po-
tentiated considerably (positive feedback) when IP3 is
allowed to elevate [Ca2 ]i above the resting level. This
positive feedback occurs in  5 s.
Finally, we measured modulation of KCNQ2/3 cur-
rent under these three calcium conditions. Since the
electrophysiology experiments were done with whole-
cell clamp, the Ca2  buffers were introduced via the re-
cording pipette (see MATERIALS AND METHODS
and legend). The current measurements (Fig. 8, E and
F) show that KCNQ2/3 current is quickly and com-
pletely suppressed after a 20-s exposure to oxo-M if
[Ca2 ]i is left unbuffered (    7   0.3 s, n   5; inhibi-
tion   98   2%); it is more slowly and less completely
suppressed if [Ca2 ]i is kept at resting levels (    
14.3   1.6 s, n   6; inhibition   75   4%); and it is un-
affected by oxo-M if [Ca2 ]i is kept below normal (inhi-
bition   4   2%, n   5). Thus the calcium depen-
dence of signaling to KCNQ current parallels that of
PLC activation.
Does Ca2  entry play a role in regulating PLC as well?
An enhancement of the [Ca2 ]i rise and of PLC activity
by extracellular calcium is evident in experiments with
longer exposures to oxo-M (Fig. 9). Consider the time
course of [Ca2 ]i during 180-s oxo-M exposures as ex-
tracellular Ca2  is altered. Fig. 9 (A–C) shows [Ca2 ]i
responses to two successive oxo-M applications. In the
control condition, oxo-M evokes a transient elevation
of [Ca2 ]i  1  M that decays to a plateau of several
hundred nanomolar until oxo-M is removed. The sec-
ond application evokes a similar, often slightly less ro-
bust, response with the standard bathing medium (Fig.
9 A; n   15) but a smaller transient and no plateau if
done in Ca2 -free medium (Fig. 9 B; n   5). If the me-
dium Ca2  is restored partway through the oxo-M expo-
sure, the [Ca2 ]i rises up again (Fig. 9 C; n   5). These
observations are the signatures of a late, store-operated
Ca2  entry. Apparently oxo-M induces an initial tran-
sient release of intracellular Ca2  that in tsA cells is fol-
lowed by opening of store-operated channels on the
plasma membrane. These plasma membrane channels
maintain the [Ca2 ]i plateau, but shut quickly after ag-
onist is removed. Fig. 9 (D–F) shows translocation of
the IP3/PIP2 probe, PH-EGFP, in parallel experiments.
The records resemble those of the [Ca2 ]i transients.
Namely, the translocation is decidedly attenuated and
decays more rapidly when the bath has Ca2 -free solu-
tion (Fig. 9 F; n   4), and it is augmented if Ca2  is re-
stored while oxo-M is still being applied (Fig. 9 E; n  
4). Thus, the activity of PLC is signiﬁcantly increased
Figure 9. Store-operated Ca2  entry potentiates activation of
PLC. (A–C) Time course of [Ca2 ]i increase during two applica-
tions of oxo-M (black bars). Each record from a single cell. The
bath contains 2 mM Ca2  most of the time, except during white
bars in B and C when it is a Ca2 -free solution with 0.5 mM EGTA.
(D–F) Mean time course of rise of normalized cytoplasmic ﬂuores-
cence of PH-EGFP during two applications of oxo-M (n   4–6,
SEM not shown ranges from 5–20%). Bath solutions as in A–C.254 Regulation of PLC, PIP2, and M Current
not only by IP3-evoked Ca2  release but also by the sub-
sequent store-operated Ca2  entry.
We used one more approach to test the calcium de-
pendence of muscarinically activated PLC. By overex-
pression of the enzyme, type I IP3-5-phosphatase (IP3-5-
P), which catalyzes the ﬁrst step in IP3 degradation, we
could abort the PLC-generated rise of IP3 concentra-
tion and consequently the IP3-induced elevation of
[Ca2 ]i. Fig. 10 (A and B) shows that expression of IP3-
5-P effectively eliminates the muscarinic [Ca2 ]i tran-
sient, presumably because IP3 is degraded as soon as it
is made. Further, Fig. 10 (C–F) shows that expression of
IP3-5-P slows and decreases the muscarinic translocation
of the DAG probe, C1-EGFP, and the PIP2/IP3 probe,
PH-EGFP. These two measures report that the PLC re-
sponse is weakened but not abolished when IP3 buildup
and Ca2  release are prevented. They suggest that PIP2
is only partially depleted by 3 min of oxo-M when IP3-5-P
prevents the positive feedback by Ca2 . With the PH-
EGFP probe there is almost no translocation when IP3-5-
P is expressed. Presumably, the combination of some
unhydrolyzed PIP2 remaining in the plasma membrane
and no IP3 accumulating in the cytoplasm means that
the PH-EGFP probe remains membrane bound. The
ﬁnal experiment measures muscarinic suppression of
KCNQ2/3 current for comparison with the observa-
tions on PLC. The suppression is slow and only partial
in the IP3-5-P cells, as expected if PLC is slowed, PIP2 is
cleaved more slowly, and much PIP2 remains.
Morphological Effects of our Reagents
We report here brieﬂy several consistent additional ef-
fects of our reagents on the morphology of the tsA
cells. When oxo-M was perfused onto cells, successive 5-s
images show considerable agitation in the cell surface
region. The membrane appears to be bubbling out in
blebs and small extensions. Presumably this motion re-
ﬂects local breakdown of the actin cytoskeleton and
perhaps an arrest of endocytosis as plasma membrane
PIP2 becomes depleted (Rohrbough and Broadie,
2005). A second set of observations is that application
of U73122 slowly causes cells to round up irreversibly
and occasionally leads to an abrupt enhancement of
nuclear envelope permeability indicated by a sudden
diffusion of the optical probes into the nucleus ( 5 s);
NEM induces blebbing; and edelfosine slowly induces
cell swelling (although KCNQ current remains) and
eventual lysis. NEM also strongly blocks diffusional ex-
change of probes between the nucleus and cytoplasm
as if it closes nuclear pores.
DISCUSSION
Comparison with Previous Observations on PIP2 and PLC
We have used three functional assays and one bio-
chemical assay to monitor the effects of PLC on phos-
phoinositide metabolism. The concordance of the re-
sults obtained with all methods validates their use and
strengthens our conclusions. All approaches agreed
that activation of endogenous PLC, presumably mostly
Figure 10. The IP3 pathway potentiates activation of PLC. Each
left panel shows experiments on a representative control cell and
a representative cell transfected 24–48 h earlier with IP3-5-
phosphatase (IP3-5-P), and the right panel shows means of 5–16
cells. (A and B) Time course and peak [Ca2 ]i rise during a 1-min
application of oxo-M. *, P   0.001, compared with control. (C and
D) Time course, amplitude, and time constant of KCNQ2/3
current inhibition during 1-min applications of oxo-M. **, P  
0.01, compared with % inhibition of control. ***, P   0.01, com-
pared with   of control. (E and F) Time course, amplitude, and
time constant of decrease of cytoplasmic C1-EGFP ﬂuorescence
during 3-min applications of oxo-M. *, P   0.001, compared with  
of control. (G and H) Time course and peak amplitude of increase
of cytoplasmic PH-EGFP ﬂuorescence during 3-min applications of
oxo-M. *, P   0.001, compared with control.Horowitz et al. 255
the  -isoform(s), by M1 receptors expressed in tsA and
CHO-M1 cells strongly depletes both the functional
plasma membrane PIP2 and the total cellular PIP2 in
less than 1 min, producing IP3-dependent Ca2  release
and DAG. According to the translocation probes, the
majority of free cellular PIP2 is conﬁned to the plasma
membrane, and DAG, which is initially not abundant, is
produced primarily in the plasma membrane. The
rapid and powerful depletion of PIP2 and considerable
depletion of PIP agree well with biochemical measure-
ments in the SH-SY5Y human neuroblastoma cell line
(Willars et al., 1998) and contrast with observations in
heart and cell cultures in which Gq/PLC-coupled re-
ceptors may be less prevalent (Nasuhoglu et al., 2002b).
The results show that the cells we used have a large en-
dogenous reserve of PLC activity that can couple to in-
troduced receptors. We ﬁnd that KCNQ2/3 channel
activity closely follows the overall changes of PIP2 in re-
sponse to a wide range of treatments. KCNQ current is
therefore a sensitive and useful indicator of PIP2 that
appears to report global PIP2 levels rather than a pri-
vate “local pool” in these experiments.
We have published a kinetic model containing tenta-
tive estimates of the time course of phosphoinositide
turnover following M1 receptor activation (Suh et al.,
2004). The model considered plasma membrane PI,
PIP, and PIP2 and four principal enzymes of phospho-
inositide metabolism: a PI-4-kinase to make PIP from PI,
a PI(4)P-5-kinase to make PIP2 from PIP, a PI(4,5)P2-5-
phosphatase to reverse the former step, and a PIP2-
speciﬁc PLC that hydrolyzes PIP2. Calculations with
that model predict severe depletion of PIP2, with only
0.66% remaining for a 60-s exposure to 10  M oxo-M,
and moderate depletion of PIP, with 40% remaining.
On the other hand, using a chemical assay, we now ﬁnd
that 7% of total cellular PIP2 and only 12% of the PIP
remain under these conditions (Fig. 6). How can these
differences be reconciled? We start with PIP2. Some
fraction of the total cellular PIP2 may not be readily ac-
cessible to the PLC that is activated by M1 receptors and
Gq because this fraction resides on membranes other
than the plasma membrane or is very tightly seques-
tered or segregated from PLC. For example, PIP2-bind-
ing proteins and lipid rafts might be able to remove
PIP2 from the accessible pool (Yin and Janmey, 2003)
such that this PIP2 fraction is not hydrolyzed in the ﬁrst
minute. Nevertheless, in terms of this concept of dis-
tinct pools of lipids we have to conclude that at least
93% of the total cellular PIP2 and 88% of the PIP form
large accessible pools at the plasma membrane, sug-
gesting that any other functional pools that may exist
are small. The large pool of PIP2 is reported by KCNQ
current and by translocation of PH domain probes.
What about the greater-than-predicted loss of PIP,
also reported by Willars et al. (1998)? In our model, a
small depletion of PIP arises because the combination
of PI(4)P-5-kinase and PI(4,5)P2-5-phosphatase acts in
a cycle to make PIP partially dependent on PIP2 by
feedback via PI(4,5)P2-5-phosphatase. The decline of
PIP could be speeded and intensiﬁed in the model by
speeding both enzymes of this cycle, making PIP more
tightly coupled to PIP2. However, another more likely
possibility is that PLC  can hydrolyze PIP in addition to
PIP2, contrary to many current descriptions. Early in
vitro biochemical experiments with vesicles containing
PI, PIP, or PIP2 led Wilson et al. (1984) and Ryu et al.
(1987a) to propose that PLC hydrolyzes PI, PIP, and
PIP2 in a Ca2 -dependent manner. If we neglect com-
plications of separate pools, our model could deplete
the PIP to a steady state of 12% (as observed) by assum-
ing that PLC hydrolyzes PIP with a rate constant that is
1/7 of that for PIP2. The predicted depletion is rela-
tively fast with a time constant of 14 s. (See APPENDIX
for further analysis of the Suh et al., 2004, model.) If,
however, we introduce an inaccessible pool of PIP, then
the rate constant of PIP hydrolysis would have to be
made more similar to that for PIP2.
Comparison with Previous Observations on Calcium 
and PLC
Our functional assays concur in ﬁnding that in the liv-
ing cell, the activation of PLC  by M1 receptors is
slowed if [Ca2 ]i is not permitted to rise above resting
levels and is stopped if [Ca2 ]i is kept well below resting
levels. The activation is greatest if an IP3-dependent
Ca2  release occurs that is allowed to raise the [Ca2 ]i
to micromolar levels. Store-operated entry of Ca2 
from the outside also can contribute to maintaining
PLC activity, but stops as soon as the receptor agonist is
removed. The positive feedback by calcium is signiﬁ-
cant. When it is permitted, the activation of PLC may
become 10–15-fold greater than when it is not permit-
ted, according to our model. These properties make
PLC  a coincidence detector that responds strongly to
simultaneous activation of receptors and rise of Ca2 
(Hashimotodani et al., 2005). For example, a postsyn-
aptic membrane with colocalized Ca2 -permeable iono-
tropic glutamate receptors and Gq-coupled metabotro-
pic glutamate receptors might activate PLC powerfully.
This calcium dependence agrees well with the re-
ported in vitro calcium dependence curve for PLC 
(Ryu et al., 1987b; Smrcka et al., 1991; Biddlecome et
al., 1996). It also agrees qualitatively with previous ex-
periments reporting an arrest of receptor-stimulated
phosphoinositide turnover when digitonin- or electro-
permeabilized cells are exposed to EGTA, and an accel-
eration when exposed to solutions with elevated cal-
cium (Fisher et al., 1989; Wojcikiewicz et al., 1994). The
reports known to us indicate that the phosphoinosi-
tide PLC enzyme activity falls virtually to zero in the ab-256 Regulation of PLC, PIP2, and M Current
sence of Ca2 , and the rates of hydrolysis by Gq-acti-
vated PLC  are strongly sensitive to Ca2  in the region
around the 100 nM typical resting concentration. The
experiments with permeabilized cells agree that cal-
cium concentrations achieved during cell signaling do
not activate the   isoforms of PLC by themselves. How-
ever, calcium is a requirement for PLC  activation by
Gq. It remains to be established whether PLCs besides
PLC  become involved in the response ampliﬁcation
by Ca2 . The crystal structure of mammalian PLC  has
an essential Ca2  ion in the active site that can coordi-
nate with one of the phosphate groups of the substrate
(Essen et al., 1996), and that isoform is an excellent
candidate for direct activation by physiological Ca2 
signals, in particular by nearby plasma membrane Ca2 
channels (Kim et al., 1999).
Optical Probes as Indicators of PI Metabolism
The behavior of the PH-EGFP and C1-EGFP probes
in our study ﬁts well with their original description
as probes of PIP2/IP3 and of DAG (Oancea et al.,
1998; Stauffer et al., 1998; Várnai and Balla, 1998; Hir-
ose et al., 1999). Both probes clearly have access to
the nucleus, and they undergo a slow, NEM-sensitive
exchange between nucleus and cytoplasm when the
probe concentration differs between these two com-
partments. This exchange seems symmetrical and pas-
sive. It adds transient components to the time course of
cytoplasmic probe, which so far as we know have not
been recognized previously. The transients ﬁt a simple
three-compartment, passive model. The diffusion of
unfused EGFP through nuclear pores of COS-7 cells
has been studied by ﬂuorescence recovery after pho-
tobleaching. In those cells, diffusional exchange of
EGFP (27 kD) is characterized by a time constant and
nuclear membrane permeability of     164 s and Pnuc  
0.011  m s 1 (Wei et al., 2003). For the larger C1-EGFP
probe (34 kD) we found     188 s and Pnuc   0.005  m
s 1, and for PH-EGFP (41 kD),     281 s and Pnuc  
0.0032  m s 1 (see Fig. 11 and calculations in APPEN-
DIX and computer program in online supplemental
material). These diffusion properties ﬁt well with the
concept of lower permeability for a larger molecule,
giving the expected permeability sequence EGFP   C1-
EGFP   PH-EGFP.
There has been some argument whether PH-EGFP
might be viewed as a pure PIP2 probe or as a pure IP3
probe, despite being able to bind to both compounds.
One line of argument used to support a pure “IP3 hy-
pothesis” was that the measured afﬁnity for IP3 is 10–
20 times higher than for PIP2 (Lemmon et al., 1995;
Hirose et al., 1999). In our discussion of the kinetic
model of Suh et al. (2004) in APPENDIX, we conclude
that our results and other published work with the PH
domain probe in cells are not compatible with the
large difference in afﬁnity measured by binding stud-
ies on puriﬁed components. A second argument for
this hypothesis was that IP3 will displace PH domains
from PIP2-containing cell membranes (Hirose et al.,
1999), but in all cases the amount of IP3 needed ex-
ceeds that expected in cells (see APPENDIX). A third
argument was that expression of the enzyme IP3-5-P
can stop migration of the probe despite activation of
PLC (Okubo et al., 2004), as we also found. It was pre-
sumed that the only change with IP3-5-P expression
was that IP3 did not accumulate. However, we have now
shown that this maneuver stops calcium feedback to
PLC and in our case slowed it so much that PIP2 hydro-
lysis was no longer complete. Thus we suggest that ex-
periments with IP3-5-P do not settle the argument. We
prefer the viewpoint that the PH probe responds to
both the PIP2 precursor and the IP3 product, and dur-
ing an experiment their relative importance changes
as their relative concentrations change. This approach
is suggested by the results of Xu et al. (2003) and
Winks et al. (2005).
Does m-3M3FBS Activate PLC?
We had hoped to develop other practical ways to acti-
vate PLC for our experiments. Agonist properties of
m-3M3FBS had been discovered in a large chemical
screen against responses of neutrophils (Bae et al.,
2003). It was reported to enhance superoxide produc-
tion, increase intracellular Ca2 , promote IP3 produc-
tion, and to activate puriﬁed PLCs of the  ,  , and  
classes directly in vitro. The effects were not sensitive to
pertussis toxin or to expression of RGS2. A later work
found a Ca2  rise but could not conﬁrm activation of
PLC either chemically or with the PH-EGFP transloca-
tion probe (Krjukova et al., 2004). In our work, we have
seen all the effects expected for an activator of PLC
(translocation of PH-EGFP, translocation of C1-EGFP,
and decrease of KCNQ2/3 current) and conclude that
50  M m-3M3FBS does activate PLC relatively strongly.
However, it is slow to act, has a variable long latency,
and a ﬂuctuating response. The ebb and ﬂow of trans-
location probes and current with m-3M3FBS suggest
that conﬂicting signal systems are activated and the bal-
ance sometimes favors turning on PLC and sometimes,
turning off. In the end, PLC turns on in our conditions.
Perhaps in other cells and under different application
conditions the putative turning-off process might win.
Variability of response, photolability, ﬂuorescence, and
spectral overlap with the common Ca2  indicator fura-2
(Jansen et al., 2004) could limit the applicability of this
compound in experiments with intact cells.
U73122 and Alkylation
PubMed lists over 1,500 papers with U73122 in the ab-
stract. The large majority use the inhibitor simply as aHorowitz et al. 257
tool to check that some signaling pathway requires
PLC. However, numerous papers report additional un-
expected effects, raising question whether this agent
can be used as a pharmacological tool without serious
side effects. We select results from just four early pa-
pers. The initial brief announcement of U73122 from
Upjohn reports that it inhibits partially puriﬁed PLC in
vitro when the molar ratio of Ca2 :PI in the assay was
 2, but “increased PLC activity” when the molar ratio
was 4–12 (Bleasdale et al., 1989). There are no data or
experimental details in that book chapter. A careful
study in NG108-15 neuroblastoma-glioma cells and in
dorsal root ganglion cells shows that U73122 blocks
bradykinin-induced Ca2  transients irreversibly with a
steep dose–response curve and a half-effective dose
IC50 of 200 nM for 20-min preincubations and that
U73343 is without effect (Jin et al., 1994). However,
these authors also ﬁnd a slow rise of intracellular Ca2 
in Ca2 -free bath solutions and a total block of L-type
Ca2  channels. They mention the possibility of protein
alkylation for such side effects. A study of the amount
and isotopic labeling of phosphoinositide pools in
platelets found 50% reduction of PIP and PIP2 with
15  M U73122 and a reduction in the rate of incor-
poration of phosphate and glycerol; it proposes that
U73122 may inhibit PI and PIP kinases and possibly
also stimulate lipid phosphatases (Vickers, 1993). A
patch-clamp study with pancreatic acinar cells shows
that 10  M U73122 can open plasma membrane ion
channels and it can promote release of Ca2  from intra-
cellular stores (Mogami et al., 1997). They conclude
that U73122 is not speciﬁc for PLC and mention the
possibility of alkylation.
For U73122, our observations agree with strong inhi-
bition of PLC, with a lack of speciﬁcity, and with some
of the reported side effects. We ﬁnd that a few micro-
molar U73122 blocks M1 receptor coupling to PLC vir-
tually completely in 1–2 min, conﬁrming that the com-
pound is an efﬁcacious inhibitor of G protein–coupled
PLC activation. At the same time, in a selected subset of
our observations, U73122 initiates a slow decline of
KCNQ2/3 current, a slow translocation of the PH-
EGFP probe, a slow rise of intracellular Ca2 , and in 5
min, a decrease of the PIP and PIP2 pools of the cell. In
RESULTS we presented the hypothesis that U73122 ac-
tivates PLC to  3% of its maximum activity while un-
coupling signaling from Gq-coupled receptors. This hy-
pothesis is consistent with the subset of results men-
tioned so far, but it does not explain for example why
U73122 fails to induce a slow translocation of the C1-
EGFP probe to the membrane. We can consider several
alternative hypotheses. For example, inhibition of lipid
kinases by U73122 (Vickers, 1993) would explain the
translocation results, the decline of KCNQ2/3 current,
and the fall of PIP and PIP2 pools accompanied by a
rise of PI; however, it does not explain the slow rise in
Ca2 . An activation of lipid phosphatases might look
similar. Finally, the highly lipid-soluble cation U73122
might sequester anionic PIP2 much as the lipid-soluble
local anesthetic benzocaine has been proposed to in-
hibit PIP2-sensitive GIRK K  channels by sequestering
PIP2 (Zhou et al., 2001). Sequestration of PIP2 could
lead to a decline of KCNQ2/3 current and a transloca-
tion of the PH-EGFP probe. Hydrophobic interactions
might even release some C1-EGFP from the membrane
if DAG is also sequestered by U73122. To speculate fur-
ther, IP3 receptors of the endoplasmic reticulum may
be held in check by contact with PIP2 on the plasma
membrane (Lupu et al., 1998; Glouchankova et al.,
2000), and if the available PIP2 is reduced by sequestra-
tion, IP3 receptors could become active, releasing Ca2 
from internal stores. Although it will not be anchored
to proteins in the membrane by alkylation, the control
compound U73343 is a hydrophobic cation as well and
should share some of these effects, as it does weakly.
The sequestration hypothesis does not explain why PIP
and PIP2 pool sizes fall with U73122. We feel that
U73122 is a complex agent with multiple molecular ac-
tions, so it is not required that a single mechanism ex-
plain all the results. Perhaps all the mechanisms men-
tioned in this paragraph play some part in the overall
effect.
Now we consider alkylation. U73122 and its control
compound differ in that the active compound can al-
kylate and the control compound cannot. Our experi-
ments comparing the two reactive maleimide com-
pounds NEM and U73122 convince us that alkylation
explains many side effects. There is a mutual mim-
icry or occlusion of effects. Either compound by itself
quickly increases KCNQ2/3 currents, shifts their volt-
age dependence, and blocks Gi/o-coupled signaling
to GIRK channels. Prior reaction with NEM prevents
U73122 from either rapidly increasing KCNQ2/3 cur-
rent or slowly decreasing it, and from inducing trans-
location of the PH-EGFP probe. Prior reaction with
U73122 prevents NEM from augmenting KCNQ2/3
current. U73122 acts at 20-fold lower concentration
than NEM, as might be expected for a maleimide with a
lipophilic tether. When the reaction occurs, the entire
aminosterol molecule (Fig. 2 A) will be coupled to the
protein target, e.g., to the KCNQ channel subunit, or
to G o, etc. NEM may mimic U73122 in another re-
spect. Longer exposures to NEM depress the pool of
cellular PIP2 and PIP, which might reﬂect inhibition of
lipid kinases. For example, NEM and other sulfhydryl
reagents block the stimulatory effects of ATP on ion
transport activity that are now known to represent lipid
kinase activity (Hilgemann and Collins, 1992).
A question we lack evidence about is whether U73122
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yes, since block is irreversible and the control com-
pound U73343 is not able to alkylate. However, al-
though NEM slows receptor-coupled PLC (Fig. 5, A and
D) it deﬁnitely does not stop it (in 2 min), and prior
NEM does not prevent subsequent U73122 from fully
arresting receptor-coupled PLC (Fig. 5 B). Thus 2.5–5
 M U73122 must react quickly with at least one cys-
teine of PLC that 100  M NEM reacts with much more
slowly or not at all. Perhaps the sterol moiety of U73122
guides it to this target.
The dose–response relation for U73122 action is of-
ten steep and seemingly variable. Several factors proba-
bly contribute to the variability: the compound is difﬁ-
cult to dissolve and needs vigorous vortexing in a
hydrophobic vehicle; it precipitates from the stock so-
lution in the refrigerator; maleimides are unstable
once placed in water; and ﬁnally alkylation is irrevers-
ible, so there is no equilibrium binding. The reaction
rate is likely to be directly proportional to the inhibitor
concentration and fairly temperature dependent. Thus
20 min at 200 nM (Jin et al., 1994) is likely to be similar
to 2 min at 2  M, provided the temperature is the
same. In brief, many factors make U73122 a difﬁcult
compound to work with. To avoid excessive side reac-
tions, the product of concentration and duration of
treatment should be kept as low as possible. In our
hands edelfosine (ET-18-OCH3) seemed a cleaner re-
agent although it was clearly cytotoxic and slow to act
and may well have its own side effects.
Conclusions
We draw several conclusions. First, under a variety of
new test conditions, the size of KCNQ current contin-
ues to be a consistent reporter of the cellular PIP2 pool.
Second, the strict Ca2  dependence of receptor-acti-
vated PLC  within the living cell subjects the enzyme
both to strong positive feedback via its own IP3 pathway
and to strong enhancement by nearby coincident Ca2 
signaling in other systems. Third, the pharmacological
tools for inhibiting and activating PLC must be used
with caution. Fourth, the PIP2 levels in cells transfected
with M1 muscarinic receptors undergo rapid and ex-
tensive depletion during receptor activation, whether
monitored indirectly via KCNQ channel activity, ﬂuo-
rescent indicators of PIP2 and DAG, or directly via total
phosphoinositide measurements. Clearly, in the cell
lines we used, receptor-activated PLCs have rapid ac-
cess to the major PIP2 pool of the cell. Work in other
systems has suggested that the PIP2 used in IP3 signal-
ing may instead be a small and highly compartmental-
ized pool of total cell PIP2, a conclusion reached for ex-
ample by using RNAi-mediated knock-down of individ-
ual lipid kinases (Wang et al., 2004). It remains to be
seen how such contrasting impressions of PIP2 signal-
ing will be resolved.
APPENDIX
Diffusion of Probes into the Nucleus
An Elementary Model for Nuclear–Cytoplasmic Exchange of
Probes. We observed that the translocation probes en-
ter the nucleus slowly and recognized that this slow ex-
change would add transients to the measured values of
cytoplasmic probe concentration. An elementary ki-
netic model was formulated to simulate the transloca-
tion of probes between plasma membrane, cytoplasm,
and nucleus. The goal was to ask how adding the nu-
clear compartment alters the expected time course of
cytoplasmic probe concentration changes.
In rough accord with images in Fig. 1 A, the cell was
taken as a sphere with radius rC   6  m, and the nu-
cleus, as a sphere with radius rN   4.4  m. This makes
the area of the nuclear membrane AN   273  m2 and
the volumes of the cytoplasm and nucleus, VC   0.55
pl and VN   0.36 pl, respectively. Flux FPr (units, mol
s 1) of probe from cytoplasm to nucleus was assumed
to obey the standard passive permeability equation
(Hille, 2001) FPr   P NAN(PrC   PrN)*10 15, where
PN is the nuclear membrane permeability to probe
(units,  m s 1), PrC and PrN are free cytoplasmic and
nuclear probe concentrations (units, M), and 10 15
converts from liters to cubic micrometers. The rate of
change of nuclear probe concentration would be
dPrN/dt   F Pr/VN and similarly for the cytoplasmic
concentration.
To simulate reversible release and binding of probe
to a membrane ligand (e.g., to free PIP2 or DAG lipid,
Lf), the probe and lipid were assumed to undergo a
conventional bimolecular reaction at the membrane
with rate constants kon and koff (units, M 1 s 1 and s 1),
such that the rate of change of membrane-bound
probe (PrM) is dPrM/dt   konPrCLf   koffPrM. To avoid
introducing surface concentration units, the lipid-
bound probe and the free lipid are treated as though in
solution throughout the cell volume, although both are
actually only on the membrane. This has no effect on
the calculated time courses but simpliﬁes the units. In
these units, the equilibrium dissociation constants
(Kd   koff/kon) for the probe–lipid complexes were taken
as 1.2  M for PIP2 and PH-EGFP and 3  M for DAG
and C1-EGFP. These apparent dissociation constants
are overestimates in the sense that they do not take into
account the possibility that most of the PIP2 or DAG
lipid may already be involved in other protein–lipid in-
teractions. The known interaction of PH-EGFP with IP3
was ignored, a shortcoming that has no inﬂuence on
the nuclear–cytoplasmic exchange time that is the fo-
cus of the model. In the following section, Kds for PH-
EGFP are used in a much more complex model, and a
lower Kd is needed for PIP2 because there the IP3 com-
petition is included.Horowitz et al. 259
Finally, the ligand (PIP2 or DAG lipid) was assumed
to be produced at a rate kprod (zeroeth order, M s 1)
and destroyed with a rate constant kdest (ﬁrst order, s 1)
so that the total rate of change of the free membrane
lipid is dLf/dt   k prod   k destLf   dPrM/dt. The total
amount of probe (0.5  M) was set below the total
amount of lipid (5  M for PIP2), so that binding to the
probe would not strongly deplete the lipid. Activation
of muscarinic receptor was simulated by increasing kdest
(for the PIP2/IP3 probe) or increasing kprod (for the
DAG probe) during the oxo-M application. The com-
plete program for the model is available in the online
supplemental material (available at http://www.jgp.
org/cgi/content/full/jgp.200509309/DC1). The model
was solved by Euler (ﬁrst-order) integration using time
steps of 25 ms in the Igor Pro programming environ-
ment (Wavemetrics).
Results of the Simple Exchange Model. Fig. 11 summarizes
the main results after free parameters were manually
adjusted to simulate the observations of Fig. 1 B. The
model does simulate transients in the changes of cyto-
plasmic probe concentrations that continue well after
the assumed lipid concentration changes brought on
by agonist addition or removal are ﬁnished. Thus, PIP2
is depleted during the two oxo-M applications, so the
PH-EGFP probes translocate from the membrane to
the cytoplasm, and then some of these probe molecules
equilibrate into the nucleus (PN   0.0032  m s 1, ex-
ponential exchange time,    281 s). Similarly, mem-
brane DAG rises during oxo-M so the C1-EGFP probes
translocate from the cytoplasm to the membrane, and
additional probe molecules then equilibrate from the
nucleus (PN    0.005  m s 1, exponential exchange
time,      188 s). The transients and the nuclear
changes during onset and recovery resemble the mea-
sured time courses well enough to show that most if not
all of the observed overshoots and decays can be under-
stood as exchange of probe between cytoplasm and
nucleus without postulating desensitizations and re-
bounds in the signaling from M1 receptors.
Relationship of the PH Probe and C1 Probe Work to our 
Larger Kinetic Model of Phosphoinositide Metabolism
We discuss brieﬂy the large kinetic model of Suh et
al. (2004), which was tentatively formulated to de-
scribe muscarinic suppression of KCNQ current in 10–
20 s, recovery of current after removal of agonist in
 200 s, and perturbation by cytoplasmic Mg2  deple-
tion and nucleotide analogs. That larger model was
implemented in the Virtual Cell environment of the
National Resource for Cell Analysis and Modeling, Uni-
versity of Connecticut Health Center (http://www.
nrcam.uchc.edu). The revised working model with
control values of rate constants and initial condi-
tions is available at that web page for public use and
modiﬁcation.
In DISCUSSION we indicated a need to add cleavage
of PIP by PLC to this model to account for the strong
measured muscarinic depletion of PIP (Fig. 6). We con-
sider here incorporating the translocation probes and
the overexpression of the IP3-phosphatase, IP3-5-P, into
the model. Since the model “cell” starts with 5  M PIP2
in the plasma membrane (referred to total cell vol-
ume), a sudden activation of PLC that hydrolyzes all
the PIP2 would produce 5  M DAG and 5  M IP3. The
PH probe binds to PIP2 and IP3 and the C1 probe binds
Figure 11. Elementary model of the exchange of optical probes
between cytoplasmic and nuclear compartments. (A) Simulated
time course of PIP2 lipid (blue dashed line), cytoplasmic PH-EGFP
(green symbols), and nuclear PH-EGFP (red line) during two
applications of oxo-M. PN   0.0032  m s 1, kon   0.4   106 M 1
s 1, koff   0.5 s 1, initial Lf   5   10 6 M, kprod   8.5   10 9 M s 1,
kdest   0.0085 s 1 at rest, and is 50 times higher during oxo-M
treatment. Conditions chosen to mimic Fig. 1, B and C. (B) Simu-
lated time course of DAG lipid (blue dashed line), cytoplasmic
C1-EGFP (green circles), and nuclear C1-EGFP (red line) during
two applications of oxo-M. PN   0.005  m s 1, kon   105 M 1 s 1,
koff   0.3 s 1, initial Lf   2.5   10 8 M, kprod   0.55   10 9 M s 1 at
rest, and kdest   0.022 s 1. During oxo-M stimulation, kprod is
multiplied by the time function, 14   140 * exp( t/5), where t is
time (units, s) after the beginning of the stimulus, simulating a
burst of DAG production before PIP2 is depleted.260 Regulation of PLC, PIP2, and M Current
to DAG, a species not present in the original model.
Therefore we added DAG as a species formed by PLC
and added its breakdown/metabolism with a rate con-
stant k   0.013 s 1, chosen to produce a time constant
of 75 s for decline of DAG after agonist withdrawal as in
Fig. 1 G. The rate constant for IP3 breakdown by endog-
enous IP3-5-P was k   0.066 s 1, chosen to produce a
time constant of  15 s for decline of IP3 (not a value
we measured).
Probes were assumed to be expressed at 0.5  M con-
centration and to undergo reversible bimolecular inter-
actions with their ligands. Published calorimetric mea-
surements give dissociation constants Kd of 1.7 and 0.2
 M for the interactions of the PH domain with PIP2 (in
phospholipid vesicles) or IP3 (in solution) (Lemmon et
al., 1995), and surface plasmon assay measurements
give 2.1 and 0.09  M for the same ligands (Hirose et
al., 1999). Calorimetry and plasmon assays give Kds of
10 and 6 nM for the DAG interaction of the C1A do-
main of PKC  (Ananthanarayanan et al., 2003). All
these Kds are expected to depend on the phospholipid
composition of the vesicles used in the assay (Bittova et
al., 2001).
Model simulations using the literature values for af-
ﬁnities of the PH domain gave a modest mimicry of the
translocation seen in control cells. Half of the probe
was bound to PIP2 on the “plasma membrane” at rest
and virtually all was released within 20 s of “oxo-M ap-
plication.” Then we tried to mimic the experiments
with expression of IP3-5-P. We slowed PLC 15-fold (to
represent the absence of any Ca2  rise) and speeded
the IP3-5-P in the model by 100-fold, which together re-
duced peak IP3 accumulation below 30 nM. The modu-
lation of KCNQ current and the appearance of DAG
were slowed appropriately as in the experiments of Fig.
10 (C–F). However, unlike the experiment of Fig. 10 G,
these changes did not prevent a strong translocation of
PH domain to the cytoplasm during “oxo-M applica-
tion.” The problem was that the afﬁnity of the PH
probe for membrane PIP2 was so low that any cleavage
of PIP2 would result in signiﬁcant probe translocation.
This was readily ﬁxed by lowering the Kd for the PH
domain–PIP2 interaction 20-fold to 0.1  M, approxi-
mately matching the Kd for IP3. A related discrepancy
with literature Kds is revealed in published experiments
determining what concentration of cytoplasmic IP3 is
needed to displace PH domain probes from the plasma
membrane in intact cells. To displace half of the PH
probe from the plasma membrane, Hirose et al. (1999)
needed 13  M IP3 in MDCK cells, and Winks et al.
(2005) needed 16  M IP3 in sympathetic neurons; and
van der Wal et al. (2001) found that release of 10  M
IP3 displaces only a small portion of the PH probe, 100
 M IP3 displaces much more, and hydrolysis of PIP2 in-
duced by activation of bradykinin receptors displaces
even more. Using the published Kds in our large model
predicted half release of PH domains already by 0.6
mM IP3, quite unlike these experiments, whereas using
the revised Kd for PIP2 (0.1  M) predicts half release by
7.8  M IP3. Thus the PIP2 afﬁnity in native membranes
must be signiﬁcantly higher than that in the phos-
phatidylcholine-phosphatidylserine vesicle environment
used in binding assays. As an alternative approach, one
might consider raising the PIP2 concentration in the
model from the chosen value of 5  M (corresponding
to 5,000  m 2 in the plasma membrane for a cell of 0.6
 m 1 surface-to-volume ratio). However, this approach
is inconsistent with the expected chemical content of
the plasma membrane. If the inner leaﬂet of the
plasma membrane is 50% lipid, there would be room
for 700,000 phospholipid molecules per square mi-
crometer. Raising the surface density of PIP2 20-fold
would make the inner leaﬂet 14% PIP2. In conclu-
sion, we consider that the effective in-cell Kds of the
PH probe for PIP2 and IP3 are about equal and near
0.1  M.
Model simulations using the literature Kd values for
the C1 domain were also not acceptable. The probe was
fully associated with the plasma membrane rather than
the cytoplasm in basal conditions because of its high af-
ﬁnity for the DAG formed there by the low, steady basal
activity of PLC. The discrepancy could be ﬁxed by rais-
ing the Kd 300-fold to 3  M, which allowed 75% of the
probe to be in the cytoplasm at rest. This might indi-
cate that most of the basal DAG in the membrane is se-
questered by other avid DAG-binding proteins (and the
published Kd is correct) or that adding GFP to the C1
domain greatly reduces its DAG afﬁnity. An alternative
approach would be to slow the basal PLC rate drasti-
cally so that there is less basal DAG. In turn, that would
require that PIP2 synthesis in the model be made a reg-
ulated process with a basal rate reduced by the same
factor as the basal PLC rate was reduced. We lack mea-
surements of DAG and have no basis to make choices
among these possibilities so far.
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